ProPhase Labs Inc. has released a presentation detailing its business verticals and initiatives. The presentation highlights ProPhase BioPharma's BE-Smart investigational esophageal cancer test, which aims to provide early detection for esophageal cancer with a target market of $7-14 billion. The company is working towards a strategic partnership with a major cancer diagnostic company and plans to commercialize the test either as a laboratory developed test (LDT) or in compliance with FDA requirements. Additionally, ProPhase Labs is involved in DNA Complete, focusing on Whole Genome Sequencing and Bioinformatics Direct-to-Consumer services. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.